--- title: "PepTracker Pro | Peptide Research & Education" description: "Explore peptides, understand the science, and track your research. Educational information backed by citations." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "WebSite", "url": "https://peptrackerpro.com", "potentialAction": { "@type": "SearchAction", "target": { "@type": "EntryPoint", "urlTemplate": "https://peptrackerpro.com/peptides?q={search_term_string}" }, "query-input": "required name=search_term_string" } }, { "@context": "https://schema.org", "@type": "SoftwareApplication", "name": "PepTracker Pro", "applicationCategory": "HealthApplication", "operatingSystem": "Web", "url": "https://peptrackerpro.com", "description": "Educational peptide research tracker and comparison tool.", "offers": { "@type": "Offer", "price": "0", "priceCurrency": "USD" } } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) # Your Guide to Peptide Research Explore peptides, understand the science, and make informed decisions. Educational information backed by research citations. [Start Here](/start) [Open the App](https://app.peptrackerpro.com) ## How PepTracker Pro Works ### Research Browse our peptide directory with detailed overviews, evidence ratings, and safety information. ### Compare Select up to 4 peptides and compare them side-by-side on key factors. ### Track Use the free PepTracker Pro app to log your peptide stack, set dosing reminders, and keep organized research notes — all in one place. Free App ## Featured Peptides [View all](/peptides) ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. [Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Energy](/benefits/energy) [View Details](/peptides/5-amino-1mq) [\+ Compare](/compare?select=5-amino-1mq)[](https://app.peptrackerpro.com/?add=5-amino-1mq) ### Abaloparatide High Evidence Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label. [Bone Growth](/benefits/bone-growth)[rare-disease-treatment](/benefits/rare-disease-treatment)[Hormone Support](/benefits/hormone-support)[disease-modification](/benefits/disease-modification)+1 more [View Details](/peptides/abaloparatide) [\+ Compare](/compare?select=abaloparatide)[](https://app.peptrackerpro.com/?add=abaloparatide) ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. [Fat Loss](/benefits/fat-loss)[appetite-control](/benefits/appetite-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/accg-2671) [\+ Compare](/compare?select=accg-2671)[](https://app.peptrackerpro.com/?add=accg-2671) ### AI-Discovered Antimicrobial Peptides Medium Evidence A new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens. [antimicrobial](/benefits/antimicrobial)[drug-resistance](/benefits/drug-resistance)[infection-treatment](/benefits/infection-treatment)[drug-discovery](/benefits/drug-discovery) [View Details](/peptides/ai-antimicrobial-peptides) [\+ Compare](/compare?select=ai-antimicrobial-peptides)[](https://app.peptrackerpro.com/?add=ai-antimicrobial-peptides) ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/aleniglipron) [\+ Compare](/compare?select=aleniglipron)[](https://app.peptrackerpro.com/?add=aleniglipron) ### ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/alv-100) [\+ Compare](/compare?select=alv-100)[](https://app.peptrackerpro.com/?add=alv-100) ## The app does what the website can't ### Dosing Reminders Set custom schedules and get notified ### Research Log Keep timestamped notes tied to each peptide ### Stack Management Track everything you're running in one dashboard [Open the Free App](https://app.peptrackerpro.com) 49 Peptides Profiled 80+ Glossary Terms 100% Free to Use ## Browse by Benefit [Sleep](/benefits/sleep)[Recovery](/benefits/recovery)[Cognition](/benefits/cognition)[Metabolism](/benefits/metabolism)[Skin](/benefits/skin)[Inflammation](/benefits/inflammation)[Longevity](/benefits/longevity)[Mood](/benefits/mood)[Immune Support](/benefits/immune-support)[Sexual Health](/benefits/sexual-health)[Gut Health](/benefits/gut-health)[Muscle Growth](/benefits/muscle-growth) ## From the Blog [All posts](/blog) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026) Research & Compounds [ ### Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026) ](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026) Antibodies barely cross into the brain - which is why anti-amyloid Alzheimer's drugs need big infusions and still cause brain swelling. Roche's trontinemab flips the problem: it hitches a plaque-clearing antibody to a transferrin-receptor 'shuttle' that ferries it across the blood-brain barrier. Early data show some of the fastest, deepest amyloid clearance yet - with strikingly little ARIA. Here's what trontinemab is, how the Brainshuttle works, and why TRONTIER 1/2 and the new PrevenTRON prevention trial are the readouts to watch. PepTracker Pro Team August 25, 2026 8 min read trontinemabRG6102RO7126209 [Read](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ziltivekimab-novo-nordisk-corvidia-il-6-interleukin-6-monoclonal-antibody-anti-inflammatory-residual-inflammatory-risk-hscrp-crp-cantos-canakinumab-rescue-zeus-hermes-artemis-ascvd-ckd-cardiovascular-outcomes-mace-august-24-2026) Research & Compounds [ ### Ziltivekimab and the ZEUS Miss: When Crushing Inflammation Didn't Save the Heart (August 24, 2026) ](/blog/ziltivekimab-novo-nordisk-corvidia-il-6-interleukin-6-monoclonal-antibody-anti-inflammatory-residual-inflammatory-risk-hscrp-crp-cantos-canakinumab-rescue-zeus-hermes-artemis-ascvd-ckd-cardiovascular-outcomes-mace-august-24-2026) For years, cardiology chased a tantalizing idea: that quieting inflammation - not just lowering cholesterol - could prevent heart attacks. Ziltivekimab, Novo Nordisk's once-monthly anti-IL-6 antibody, was built to prove it. In July 2026 the pivotal ZEUS trial delivered a hard answer: the drug crushed inflammatory markers but did not cut cardiovascular events. Here's what ziltivekimab is, why it mattered, and what the surprising 'engagement-without-benefit' result means. PepTracker Pro Team August 24, 2026 8 min read ziltivekimabNovo NordiskCorvidia [Read](/blog/ziltivekimab-novo-nordisk-corvidia-il-6-interleukin-6-monoclonal-antibody-anti-inflammatory-residual-inflammatory-risk-hscrp-crp-cantos-canakinumab-rescue-zeus-hermes-artemis-ascvd-ckd-cardiovascular-outcomes-mace-august-24-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/eplontersen-wainua-wainzua-ionis-astrazeneca-ttr-transthyretin-galnac-antisense-oligonucleotide-aso-attr-amyloidosis-polyneuropathy-cardiomyopathy-attr-cm-neuro-ttransform-cardio-ttransform-missed-endpoint-monotherapy-august-23-2026) Research & Compounds [ ### Eplontersen (Wainua): The Antisense TTR Silencer That Missed in the Heart - What CARDIO-TTRansform Means Next to Vutrisiran's Success (August 23, 2026) ](/blog/eplontersen-wainua-wainzua-ionis-astrazeneca-ttr-transthyretin-galnac-antisense-oligonucleotide-aso-attr-amyloidosis-polyneuropathy-cardiomyopathy-attr-cm-neuro-ttransform-cardio-ttransform-missed-endpoint-monotherapy-august-23-2026) Vutrisiran silenced TTR and moved mortality. Eplontersen silences the same protein a different way - as an antisense oligonucleotide - and in July 2026 its huge ATTR cardiomyopathy trial, CARDIO-TTRansform, missed its primary endpoint. Here is how Ionis and AstraZeneca's once-monthly Wainua works, why it succeeded in nerves but stumbled in the heart, and what the monotherapy signal tells us about adding a silencer on top of tafamidis. PepTracker Pro Team August 23, 2026 8 min read eplontersenWainuaWainzua [Read](/blog/eplontersen-wainua-wainzua-ionis-astrazeneca-ttr-transthyretin-galnac-antisense-oligonucleotide-aso-attr-amyloidosis-polyneuropathy-cardiomyopathy-attr-cm-neuro-ttransform-cardio-ttransform-missed-endpoint-monotherapy-august-23-2026) ## Stay Informed Get weekly peptide research summaries and new peptide profiles. Email addressSubscribe I agree to receive educational email updates. Unsubscribe anytime. [View Privacy Policy.](/privacy) ## Track Your Research with PepTracker Pro Save peptides, log your stack, and set reminders — all in the free PepTracker Pro app. Private | Mobile-First | Offline Access [Try the Free App →](https://app.peptrackerpro.com) [Learn More](/start) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.